A generic pill has been shown to reduce hospitalisation rates in high-risk patients with early COVID-19, potentially offering a low-cost alternative to oral antivirals from Merck & Co a
Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients.
GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on Xevudy for mild-to-moderate diseas
Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitatin
Already struggling to make headway with its recently launched Alzheimer's drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis
The World Health Organization has set up a new scientific group to study the origins of COVID-19 in the hope that it will help prevent future pandemics.